Hormonal
Short-chain fatty acids (SCFAs) such as acetate and propionate regulate glucose homeostasis primarily by activating the GPCR FFAR2 on enteroendocrine L-cells, stimulating the release of GLP-1, which in turn promotes insulin secretion and improves glucose tolerance.
To leverage the glucose-lowering benefits of short-chain fatty acids, focus on consuming fermentable dietary fibers (like those in oats, legumes, and resistant starches) to feed gut bacteria. These bacteria produce SCFAs (acetate, propionate, butyrate) which activate FFAR2 receptors in your gut. This triggers the release of GLP-1, a hormone that signals your pancreas to release insulin more effectively, thereby improving blood sugar control. This is particularly beneficial if you have insulin resistance or type 2 diabetes.
Taken together, these data suggest that FFAR2 but not FFAR3, mediates the stimulatory effects of SCFAs on GLP-1 release... This suggests that the observed impairment in glucose tolerance in FFAR2-KO mice may be partly due to decreased GLP-1 levels and impaired GLP-1-stimulated insulin secretion.
Why this rating
The paper cites multiple animal knockout models, selective agonist studies, and human cell culture data supporting the FFAR2-GLP-1 axis.
Source
GPCR-mediated effects of fatty acids and bile acids on glucose homeostasis
Antwi‐Boasiako Oteng et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1206063
More from this paper
- Bile acids, particularly lithocholic acid and hyocholic acid, improve glucose tolerance by activating the GPCR GPBAR1 (TGR5) on enteroendocrine cells, leading to increased GLP-1 secretion and insulin release.Good
- Unsaturated fatty acids, particularly omega-3 PUFAs like linoleic, oleic, and docosahexaenoic acid, stimulate insulin and glucagon secretion via activation of FFAR1 and FFAR4, improving glucose tolerance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →